Les cancers à petites cellules (CPC). Prise en charge thérapeutique

作者: J.-L. Pujol , X. Quantin , W. Jacot , A. Serre , V. Fayolle

DOI: 10.1016/S0761-8425(06)72069-1

关键词:

摘要: Resume Parmi l’ensemble des tumeurs malignes, le cancer bronchique a petites cellules tient une place preoccupante en raison de son incidence epidemiologique elevee et la difficulte traitement. La demarche diagnostique est dictee par souci ne pas meconnaitre sites metastatiques. Le frequemment metastatique peut etre considere, au moment du diagnostic, comme maladie generale declaree ou potentielle. chimiotherapie donc traitement reference. Elle sera fondee moins sur bitherapie associant cisplatine l’etoposide. Dans les formes etendues, c’est-a-dire pour lesquelles contenue dans un champ d’irradiation, seule recommandee. limitees, il recommande d’associer radiotherapie selon modalite concomitante. L’irradiation cerebrale prophylactique indiquee chez patients remission complete apres chimiotherapie. L’arsenal therapeutique s’est recemment enrichi l’introduction nouvelles drogues anticancereuses developpement agents non cytotoxiques cibles entre autres processus angiogenique. reconnaissance mecanismes specifiques resistance certaines drogues, l’etude phenotypique genotypique permettra l’avenir traitements adaptes chaque cas.

参考文章(28)
Zelen M, Keynote address on biostatistics and data retrieval. Cancer chemotherapy reports. ,vol. 4, pp. 31- 42 ,(1973)
John P. Chute, Timothy Chen, Ellen Feigal, Richard Simon, Bruce E. Johnson, Twenty Years of Phase III Trials for Patients With Extensive-Stage Small-Cell Lung Cancer: Perceptible Progress Journal of Clinical Oncology. ,vol. 17, pp. 1794- 1794 ,(1999) , 10.1200/JCO.1999.17.6.1794
Joachim von Pawel, Joan H. Schiller, Frances A. Shepherd, Scott Z. Fields, J.P. Kleisbauer, Nick G. Chrysson, David J. Stewart, Peter I. Clark, Martin C. Palmer, Alain Depierre, James Carmichael, Jacqueline B. Krebs, Graham Ross, Stephen R. Lane, Richard Gralla, Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 17, pp. 658- 667 ,(1999) , 10.1200/JCO.1999.17.2.658
Daniel B. Fried, David E. Morris, Charles Poole, Julian G. Rosenman, Jan S. Halle, Frank C. Detterbeck, Thomas A. Hensing, Mark A. Socinski, Systematic Review Evaluating the Timing of Thoracic Radiation Therapy in Combined Modality Therapy for Limited-Stage Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 22, pp. 4837- 4845 ,(2004) , 10.1200/JCO.2004.01.178
T. Cerny, H. Anderson, V. Bramwell, N. Thatcher, V. Blair, Pretreatment prognostic factors and scoring system in 407 small‐cell lung cancer patients International Journal of Cancer. ,vol. 39, pp. 146- 149 ,(1987) , 10.1002/IJC.2910390204
J. Pujol, J. Breton, R. Gervais, M. Tanguy, E. Quoix, P. David, H. Janicot, A. Depierre, S. Gameroft, J. Geneve, O-159 A prospective randomized phase III, double-blind, placebo-controlled study of thalidomide in extended-disease (ED) SCLC patients after response to chemotherapy (CT) Lung Cancer. ,vol. 49, ,(2005) , 10.1016/S0169-5002(05)80293-4
J.-L. Pujol, J.-P. Daures, A. Riviere, E. Quoix, V. Westeel, X. Quantin, J.-L. Breton, E. Lemarie, M. Poudenx, B. Milleron, D. Moro, D. Debieuvre, T. Le Chevalier, Etoposide Plus Cisplatin With or Without the Combination of 4′-Epidoxorubicin Plus Cyclophosphamide in Treatment of Extensive Small-Cell Lung Cancer: a French Federation of Cancer Institutes Multicenter Phase III Randomized Study Journal of the National Cancer Institute. ,vol. 93, pp. 300- 308 ,(2001) , 10.1093/JNCI/93.4.300
D Mavroudis, E Papadakis, M Veslemes, M Agelidou, X Tsiafaki, G Agelidou, G Pavlakos, O Anagnostopoulou, Th Giannakakis, N Ziras, M Bania, Ch Lambrakis, Ch Kouroussis, G Samonis, N Bachlitzanakis, V Georgoulias, A multicenter randomized phase III study comparing paclitaxel-cisplatin-etoposide (TEP) versus cisplatin-etoposide (EP) as front-line treatment in patients with small cell lung cancer (SCLC) Lung Cancer. ,vol. 29, pp. 29- ,(2000) , 10.1016/S0169-5002(00)80091-4